Literature DB >> 33139931

New anti-osteoporosis drug target identified.

Shimona Starling1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33139931     DOI： 10.1038/s41574-020-00441-6

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Prrx1 Fibroblasts Represent a Pro-fibrotic Lineage in the Mouse Ventral Dermis.

Authors:  Tripp Leavitt; Michael S Hu; Mimi R Borrelli; Michael Januszyk; Julia T Garcia; Ryan C Ransom; Shamik Mascharak; Heather E desJardins-Park; Ulrike M Litzenburger; Graham G Walmsley; Clement D Marshall; Alessandra L Moore; Bryan Duoto; Sandeep Adem; Deshka S Foster; Ankit Salhotra; Abra H Shen; Michelle Griffin; Ethan Z Shen; Leandra A Barnes; Elizabeth R Zielins; Zeshaan N Maan; Yuning Wei; Charles K F Chan; Derrick C Wan; Hermann P Lorenz; Howard Y Chang; Geoffrey C Gurtner; Michael T Longaker
Journal:  Cell Rep       Date:  2020-11-10       Impact factor: 9.423
  1 in total
  2 in total

1.  Beraprost ameliorates postmenopausal osteoporosis by regulating Nedd4-induced Runx2 ubiquitination.

Authors:  Huo-Liang Zheng; Wen-Ning Xu; Wen-Sheng Zhou; Run-Ze Yang; Peng-Bo Chen; Tao Liu; Lei-Sheng Jiang; Sheng-Dan Jiang
Journal:  Cell Death Dis       Date:  2021-05-15       Impact factor: 8.469

Review 2.  Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?

Authors:  Christian Horst Tonk; Sarah Hani Shoushrah; Patrick Babczyk; Basma El Khaldi-Hansen; Margit Schulze; Monika Herten; Edda Tobiasch
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.